Q2 EARNINGS: Lombard's first US quarter 'encouraging', Mindray slashes sales guidance
This article was originally published in Clinica
Lombard Medical Technologies was “a bit light on results” during its first quarter as a US-listed company, noted Jefferies analyst Raj Denhoy. But more positively, “there were very encouraging signs for the commercial ramp of [its flagship product] Aorfix,” the analyst added. Aorfix is indicated for the endovascular treatment of abdominal aortic aneurysms (AAA). It got the go-ahead in the US in February 2013, and is currently the only product approved for use in patients with high-angle aneurysms of up to 90 degrees (who account for 30% of the EVAR market).